CN1276777C - SARS vaccine of adenovirus carrier and preparation method, application of coronavirus S gene - Google Patents
SARS vaccine of adenovirus carrier and preparation method, application of coronavirus S gene Download PDFInfo
- Publication number
- CN1276777C CN1276777C CN 200410044285 CN200410044285A CN1276777C CN 1276777 C CN1276777 C CN 1276777C CN 200410044285 CN200410044285 CN 200410044285 CN 200410044285 A CN200410044285 A CN 200410044285A CN 1276777 C CN1276777 C CN 1276777C
- Authority
- CN
- China
- Prior art keywords
- sars
- gene
- vaccine
- preparation
- coronavirus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 241000315672 SARS coronavirus Species 0.000 title claims abstract description 69
- 201000003176 severe acute respiratory syndrome Diseases 0.000 title claims abstract description 68
- 229960005486 vaccines Drugs 0.000 title claims abstract description 49
- 241000701161 unidentified adenovirus Species 0.000 title claims abstract description 40
- 241000711573 Coronaviridae Species 0.000 title claims abstract description 39
- 238000002360 preparation method Methods 0.000 title claims abstract description 20
- 239000000969 carrier Substances 0.000 title abstract description 8
- 230000002950 deficient Effects 0.000 claims abstract description 16
- 238000000746 purification Methods 0.000 claims abstract description 7
- 230000003321 amplification Effects 0.000 claims description 11
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 11
- 238000002347 injection Methods 0.000 claims description 6
- 239000007924 injection Substances 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 238000000926 separation method Methods 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 3
- 210000002356 Skeleton Anatomy 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 238000001890 transfection Methods 0.000 claims description 2
- 241001135569 Human adenovirus 5 Species 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 241000700605 Viruses Species 0.000 abstract description 12
- 230000003612 virological Effects 0.000 abstract description 7
- 230000036039 immunity Effects 0.000 abstract description 6
- 210000001533 Respiratory Mucosa Anatomy 0.000 abstract description 5
- 102000004965 antibodies Human genes 0.000 abstract description 5
- 108090001123 antibodies Proteins 0.000 abstract description 5
- 102000004169 proteins and genes Human genes 0.000 abstract description 5
- 108090000623 proteins and genes Proteins 0.000 abstract description 5
- 230000002163 immunogen Effects 0.000 abstract description 4
- 239000002245 particle Substances 0.000 abstract description 4
- 230000001681 protective Effects 0.000 abstract description 3
- 230000000875 corresponding Effects 0.000 abstract description 2
- 201000009910 diseases by infectious agent Diseases 0.000 abstract description 2
- 238000010255 intramuscular injection Methods 0.000 abstract description 2
- 239000007927 intramuscular injection Substances 0.000 abstract description 2
- 229920001184 polypeptide Polymers 0.000 abstract description 2
- 238000010353 genetic engineering Methods 0.000 abstract 1
- 210000004027 cells Anatomy 0.000 description 12
- 102000004190 Enzymes Human genes 0.000 description 9
- 108090000790 Enzymes Proteins 0.000 description 9
- 238000010790 dilution Methods 0.000 description 7
- 239000007759 RPMI Media 1640 Substances 0.000 description 6
- 206010003757 Atypical pneumonia Diseases 0.000 description 5
- 108010061994 Coronavirus Spike Glycoprotein Proteins 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- 210000002966 Serum Anatomy 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 102000038129 antigens Human genes 0.000 description 4
- 108091007172 antigens Proteins 0.000 description 4
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 210000003462 Veins Anatomy 0.000 description 3
- 239000012531 culture fluid Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000000241 respiratory Effects 0.000 description 3
- 210000004369 Blood Anatomy 0.000 description 2
- 210000000981 Epithelium Anatomy 0.000 description 2
- SBUJHOSQTJFQJX-NOAMYHISSA-N Kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 2
- 102000011931 Nucleoproteins Human genes 0.000 description 2
- 108010061100 Nucleoproteins Proteins 0.000 description 2
- 101710033747 S6 Proteins 0.000 description 2
- 208000001756 Virus Disease Diseases 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 241001493065 dsRNA viruses Species 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 229960000318 kanamycin Drugs 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 229920000160 (ribonucleotides)n+m Polymers 0.000 description 1
- 210000001015 Abdomen Anatomy 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- AIYUHDOJVYHVIT-UHFFFAOYSA-M Caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 1
- 241000867607 Chlorocebus sabaeus Species 0.000 description 1
- 206010011732 Cyst Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000033180 ERVK-6 Human genes 0.000 description 1
- 101710038044 ERVK-6 Proteins 0.000 description 1
- 101710027967 ERVW-1 Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 101700032567 GATM Proteins 0.000 description 1
- 210000004379 Membranes Anatomy 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N Pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 229960001412 Pentobarbital Drugs 0.000 description 1
- 101710023234 Segment 5 Proteins 0.000 description 1
- 101700028070 VPX Proteins 0.000 description 1
- 230000001154 acute Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000890 antigenic Effects 0.000 description 1
- 230000003115 biocidal Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 229940098124 cesium chloride Drugs 0.000 description 1
- 230000002596 correlated Effects 0.000 description 1
- 210000004748 cultured cells Anatomy 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000002068 genetic Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002458 infectious Effects 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000001717 pathogenic Effects 0.000 description 1
- 244000052769 pathogens Species 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000036647 reaction Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissues Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000001131 transforming Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000003442 weekly Effects 0.000 description 1
Abstract
The invention pertains to biological genetic engineering field, specificly relating to SARS vaccine of adenovirus carrier and preparation method, application of related coronavirus S gene in preparation of the SARS vaccine for preventing SARS. Through a bioengineering means, the related coronary virus S gene and a defective adenovirus are recombined, which makes protective immunogen protein or polypeptide expressing in it. A genic vaccine that can arouse the mucosal immunogenicity is produced through amplifying training, purification, and preparation, which induces a immunity reaction in the respiratory mucosa, makes the organism produce the corresponding antibody, and prevents virus from infection. Compared with the traditional inactivated viral particles vaccine, the invention has a high safety; it is convenient to operate; it is not limited by the specific conditions such as intramuscular injection; and it has an extensive clinical application prospect.
Description
One, technical field
The invention belongs to the biological gene engineering field, be specifically related to adenovirus vector SARS vaccine, its preparation method and the application of announcement associated coronavirus S gene aspect preparation prevention of atypical pneumonia (SARS) vaccine.
Two, background technology
Atypical pneumonia (atypical pneumonia) is broken out in the Chinese Guangdong area since the end of last year, morbidity is anxious, and infectiousness is strong, and antibiotic therapy is invalid.At present, this disease has been transmitted to more than 30 countries and regions, WHO with the respiratory complication of it called after serious acute (severe acuterespiratory syndrome, SARS).
At present, the scientist of world many countries all from different patients serums independent separate to novel coronavirus (coronavirus), the virus gene sequence analysis result shows, they and known coronavirus have 50%～60% homology, The World Health Organization (WHO) announces that the pathogen that causes SARS is the variant of coronavirus.
Coronavirus is a kind of RNA viruses of non-segmental normal chain, and the nearly 30kb of its genome can propagate in humans and animals, the main respiratory system that infects humans and animals, the coronavirus granule is a kind ofly to have inner core and cyst membrane bag by ground virus, has four kinds of structural protein: and spike protein (spike, S), memebrane protein (membrance, M), and envelope protein (envelop, E), and nucleoprotein (nucleoprotein, N).Because coronavirus is a kind of RNA viruses, and is very unstable, undergo mutation easily to escape host's immunological surveillance and repulsion.Therefore, must search out good stability in the SARS associated coronavirus and have the antigen of immanoprotection action, with the development of the vaccine of being correlated with.
The virus particle vaccine of present less application deactivation, because whole virus particles has been carried viral full genome, safety concerns is bigger.Though coronavirus previously easily obtains at In vitro culture, this time the coronavirus toxicity that SARS is relevant greatly and genetic background imperfectly understand, so mass preparation coronavirus granule is infeasible.The exploitation that develops into subunit vaccine of technique for gene engineering provides a great convenience, and the operability of subunit vaccine and biological safety are good.Have immunogenic virus antigen determinant if can screen, in conjunction with technique for gene engineering, can transform antigenic determinant easily, to strengthen its stability, immunogenicity, biological safety.Obviously, by technique for gene engineering, can prepare effective subunit vaccine easily.
According to studies show that at present; in the known four kinds of structural protein of coronavirus; spike protein (spike S) has the structural protein of inducing protective immunological reaction; part scholar's research structure is verified, and coronavirus spike protein C-terminal is its antigen decision family place; simultaneously; the SARS associated coronavirus causes infection by respiratory tract, and the vaccine that can prevent SARS is not arranged at present yet.
In addition, data shows, adenovirus itself is easy to infect the respiratory mucosa epithelium, more easily induce the respiratory mucosa immunoreation, and adenovirus is made the immunogen of vector expression and is expressed in host cell, processes, folds, modifies, offers, basically kept immunogenic native conformation, the biological activity height.
Described condition provides solid theory for utilizing defective adenoviral as carrier development and production adenovirus SARS vaccine.
Three, summary of the invention
First purpose of the present invention is to provide a kind of adenovirus SARS vaccine that can prevent epidemic disease " atypical pneumonia ", better prevents the generation and the propagation of " atypical pneumonia "; Another object of the present invention is to provide a kind of defective adenoviral that utilizes as carrier, by means such as gene clone, reorganization, prepares the method for adenovirus vector SARS vaccine and discloses the application of SARS associated coronavirus S gene in the preparation vaccine.
The object of the present invention is achieved like this: by the biological engineering means, (coronavirus has four structural genes with SARS associated coronavirus S gene, the S gene is one of them, detailed description sees below) combine with the defective adenoviral reorganization, constitute a kind of gene vaccine that can cause mucosal immunity originality.
Used Spike gene fragment order is:
The S gene order of being announced among the use Gene bank (Gene bank query ID:, as follows according to sequential design PCR primer gbAY278554.2) as masterplate:
V1 GGTCTAGAGT?TGTGGTTTCA?AGTGAT
V2 TTTCTAGACC?ATGGGTTGTG?TCCTTGCT
V3 TTTCTAGACC?ATGGCATATA?GGTTCAATG
V4 TAGGTACCAA?TGCCAGTAGT?GGTG
V5 TTGGTACCTC?CGCCTCGACT?TT
V6 CCGGTACCAT?AAGTTCGTTT?ATGTGT
Wherein V1 and V4 are a pair of, amplification S gene N end fragment; V2 and V5 are a pair of primer, amplification S gene M district fragment; V3 and V6 are a pair of primer, amplification S gene C end fragment (as Fig. 1), and the structure after the amplification is seen Fig. 2.
The preparation of adenovirus SARS vaccine:
At first, collect to close and separate rehabilitation patient's serum, obtain the total RNA of coronavirus, by reverse transcription, step such as check order, select and obtain the S gene by separation and Extraction.Then, the S gene clone is obtained clone body (depositary institution: Chinese typical culture collection center to the pShuttle plasmid; Preservation date: on May 17th, 2003; Preserving number: CCTCC M 203036 E.coliDH5a/pShuttle-SN and CCTCC M 203037 E.coli DH5a/pShuttle-SC), again with itself and adenovirus skeleton plasmid (pAdeno-X
TM) connect (wherein pShuttle, pAdeno-X be all available from CLONTECH Laboratory, Inc, USA).Connect the common rotaring redyeing 293 cell in back, after further purification is identified, increase in a large number with 293 cells, collect viral liquid, separation and purification is adenovirus SARS vaccine.It can make the medicament of spray or other form.The major technology route is seen Fig. 4.
The present invention is a kind of recombinant vaccine, promptly be to use the gene vaccine of defective adenoviral as carrier, the adenovirus that its utilization itself is easy to infect the respiratory mucosa epithelium expresses former albumen of protective immunity or polypeptide as carrier therein, induces the respiratory mucosa immunoreation; By the mucosa immunity-inducing reaction, make body produce corresponding antibodies, prevent virus infection.The present invention and traditional inactivated virus particle vaccine relatively, it is safe, and easy to use, not limited by specified conditions such as intramuscular injection.
At present, SARS propagates all over the world fast, as a kind of viral infectious, does not find the medicine that can effectively treat now as yet, and in such cases, prevention is best means.Confirmed that now SARS associated coronavirus spike protein C-terminal is its antigen decision family place.Therefore, the present invention is just according to this discovery, synthetic SARS associated coronavirus spike protein gene, it is cloned into adenovirus vector, form through amplification cultivation, purification, preparation, can effectively induce mucosa to produce antibody, produce humoral immunization and prevent the virus infection body, have potential applicability in clinical practice widely.
Four, description of drawings
Fig. 1 is a S gene fragment amplification sketch map.
Fig. 2 is the recombination deficient mutant adenovirus structure chart that has S gene (Spike-S).
Fig. 3 is pShuttle-Sc, pShuttle-S
M, pShuttle-S
NRecombinant enzyme action result.
Fig. 4 is pShuttle-Sc, pShuttle-S
M, pShuttle-S
NThe recombinant sequencing result.
Fig. 5 is that RT-PCR detects Ad-S
NAnd Ad-S
MThe expression result of the test
Fig. 6 is that Western blot detects Ad-S
NThe expression result of the test
Fig. 7 is Ad-S
NInjection or respiratory immunity all induce female rats to produce the expression in vivo result of the test of specific antibody (IgG)
Fig. 8 is Ad-S
NInjection or respiratory immunity all induce male rat to produce the expression in vivo result of the test of specific antibody (IgG)
Fig. 9 is the technology path figure of vaccine production of the present invention.
Five, the specific embodiment
Below will further specify the present invention by specific embodiment.
Embodiment 1
The preparation method of adenovirus vector SARS vaccine:
Two parts that the preparation of adenovirus vector SARS vaccine is divided into that make up early stage and the later stage increases:
Make up early stage:
Obtain SARS associated coronavirus spike (S
F, S
N, S
M, S
C) behind the gene, increase with PCR method, behind PCR,, use this enzyme enzyme action pShuttle simultaneously with 37 ℃ of enzyme action of Xbal+Kpnl, connect, transformed into escherichia coli DH5a utilizes kanamycin (Kan
R) the resistance screening positive colony, obtain pS behind cultivation, the purification
F/ S
N/ S
M/ S
C-Shuttle uses the l-Ceul+Pl-Scel enzyme action, uses this enzyme enzyme action PAdeno-X simultaneously
TM, connecting behind the enzyme action, transformed into escherichia coli DH5a utilizes ammonia benzyl (Amp
+) the resistance screening positive colony promptly gets pAd-S
F/ S
N/ S
M/ S
C
Amplification culture:
Obtain pAd-S
F/ S
N/ S
M/ S
CAfter, again through Pacl enzyme action, plasmid transfection incasing cells after linearize, incasing cells is for having integrated the cell line (strain) of C subclass 5 type adenovirus (Ad5) E1 district genes, for example 293 cells.Through plaque select, PCR is accredited as Ad-S
F/ S
N/ S
M/ S
CAfter, cultivate 293 cells in a large number, use Ad-S
F/ S
N/ S
M/ S
CInfect 293 cells, through the cesium chloride separation and purification, steps such as preparation promptly obtain adenovirus SARS vaccine.
The SARS vaccine comprises SARS associated coronavirus S gene and and defective adenoviral.Defective adenoviral is 5 type adenovirus, i.e. Ad5 of the C subclass that lacks fully of E1 district.The E3 district of this defective adenoviral can or not lack for disappearance or excalation fully.Dress CMV promoter and BGHpolyA in the defective adenoviral.
Ad-S
F/S
N/S
M/S
C
Be cloned in the adenovirus vector for SARS associated coronavirus S full length gene.
Be cloned into and comprise S for SARS associated coronavirus S gene in the adenovirus vector
1Domain is in interior sequence.
Be cloned into and comprise S for SARS associated coronavirus S gene in the adenovirus vector
2Domain is in interior sequence.
Be cloned into and comprise S for SARS associated coronavirus S gene in the adenovirus vector
1, S
2(base number is domain: 49～3585) in interior sequence.
Be cloned in the adenovirus vector 3686～3648) and the C end fragment (base number is: for SARS associated coronavirus S gene is striden the film district.
Embodiment 2
Be cloned in the adenovirus vector for SARS associated coronavirus S gene N end fragment.All the other are with embodiment 1.
Embodiment 3
Be cloned in the adenovirus vector for SARS associated coronavirus S gene intermediate segment.All the other are with embodiment 1.
Embodiment 4
Be cloned in the adenovirus vector for SARS associated coronavirus S gene C end fragment.
All the other are with embodiment 1.
Embodiment 5
S gene transformation pShuttle plasmid and evaluation:
With 37 ℃ of water bath condition enzyme action of Xbal+Kpnl, use this enzyme enzyme action pShuttle simultaneously, connect, transformed into escherichia coli DH5a cultivates, and utilizes kanamycin (Kan
R) the resistance screening positive colony, obtain pShuttle-Sc, pShuttle-S respectively
M, pShuttle-S
N, identify and detect Sequence Identification by conventional agargel electrophoresis, the results are shown in Figure 3, Fig. 4.
Embodiment 6
The Ad-S that the clone is obtained
N/ S
MCarry out the vivoexpression test.
Infect the VeroE6 cell with 2.5～40MOI, discard viral suspension, add cell culture fluid, cultivate under 37 ℃, 5%CO2 condition, collect the cultured cell supernatant in infecting back 48h, detect the expression of Ad-Sn and Ad-Snm respectively with the RT-PCR method, detect the expression of Ad-Sn, the results are shown in Figure 5, Fig. 6 with Western blot method.
Embodiment 7
The Ad-S that the clone is obtained
NCarry out the expression in vivo test.
Subjects is divided into groups in the following manner: Ad-Sn collunarium the group, (contrast of Ad-lacZ collunarium group, annotate anesthesia with 3% pentobarbital abdomen earlier, collunarium 0.5mL/ is only), Ad-Sn tail vein injection group, Ad-lacZ tail vein injection group (contrast, tail vein injection administration 0.5mL/ only), blank group (not doing any processing).Administration in the following manner then: be administered once continuous three weeks weekly; After the administration first time, a week get blood, last 2 week of administration the back put to death animals and get blood and tissue, measure rat anti SARS IgG concentration with the ELISA method, the results are shown in Figure 7, Fig. 8.
Embodiment 8
Green monkey kidney cell (Vero E6) cell is avoided SARS and is attacked
1. inoculation Vero E6 cell is to 96 orifice plates, 2 * 10
4/ hole.
2. after 24 hours, inoculate adenovirus SARS vaccine, method: press 4 times of virus dilution stock solutions with RPMI-1640, earlier culture fluid sucking-off in 96 orifice plates is discarded during inoculation, behind the PBS clean-out opening one time, add different dilution viral liquid, each dilution factor adds 5 holes, 50 μ L/ holes.Simultaneously with the negative contrast of RPMI-1640 (not containing virus).37 ℃, 5%CO
2, hatch 1 hour under the saturated humidity condition after, add the RPMI-1640 contain 5% new-born calf serum, 200 μ L/ holes, 37 ℃, 5%CO
2, cultivate under the saturated humidity condition.
3. after 24 hours, inoculate SARS virus, method: RPMI-1640 dilution SARS virus is to 100TCID50, earlier culture fluid sucking-off in 96 orifice plates is discarded during inoculation, behind the PBS clean-out opening one time, add different dilution viral liquid, each dilution factor adds 5 holes, 50 μ L/ holes.Simultaneously with the negative contrast of RPMI-1640 (not containing virus).37 ℃, 5%CO
2, hatch 1 hour under the saturated humidity condition after, add the RPMI-1640 contain 5% new-born calf serum, 200 μ L/ holes, 37 ℃, 5%CO
2, cultivate under the saturated humidity condition.
4. after this observed every 12 to 24 hours and record cytopathy situation, each dilution every porocyte pathological changes scoring addition draws the cytopathy index during result of calculation, gets each class mean, and is as follows:
＜110〉Zhongshan Univ. Cancer Cure Center
＜120〉Adenovirus Carrier SARS Vaccines And Its Preparation Method, the application of coronavirus S gene
<160>4
<210>1
<211>3780
<212>DNA
＜213〉virus is planted
<220>
<221>CDS
<222>(1)…(3780)
<400>1
atgtttattt?tcttattatt?tcttactctc?actagtggta?gtgaccttga?ccggtgcacc 60
acttttgatg?atgttcaagc?tcctaattac?actcaacata?cttcatctat?gaggggggtt 120
tactatcctg?atgaaatttt?tagatcagac?actctttatt?taactcagga?tttatttctt 180
ccattttatt?ctaatgttac?agggtttcat?actattaatc?atacgtttgg?caaccctgtc 240
atacctttta?aggatggtat?ttattttgct?gccacagaga?aatcaaatgt?tgtccgtggt 300
tgggtttttg?gttctaccat?gaacaacaag?tcacagtcgg?tgattattat?taacaattct 360
actaatgttg?ttatacgagc?atgtaacttt?gaattgtgtg?acaacccttt?ctttgctgtt 420
tctaaaccca?tgggtacaca?gacacatact?atgatattcg?ataatgcatt?taattgcact 480
ttcgagtaca?tatctgatgc?cttttcgctt?gatgtttcag?aaaagtcagg?taattttaaa 540
cacttacgag?agtttgtgtt?taaaaataaa?gatgggtttc?tctatgttta?taagggctat 600
caacctatag?atgtagttcg?tgatctacct?tctggtttta?acactttgaa?acctattttt 660
aagttgcctc?ttggtattaa?cattacaaat?tttagagcca?ttcttacagc?cttttcacct 720
gctcaagaca?tttggggcac?gtcagctgca?gcctattttg?ttggctattt?aaagccaact 780
acatttatgc?tcaagtatga?tgaaaatggt?acaatcacag?atgctgttga?ttgttctcaa 840
aatccacttg?ctgaactcaa?atgctctgtt?aagagctttg?agattgacaa?aggaatttac 900
cagacctcta?atttcagggt?tgttccctca?ggagatgttg?tgagattccc?taatattaca 960
aacttgtgtc?cttttggaga?ggtttttaat?gctactaaat?tcccttctgt?ctatgcatgg 1020
gagagaaaaa?aaatttctaa?ttgtgttgct?gattactctg?tgctctacaa?ctcaacattt 1080
ttttcaacct?ttaagtgcta?tggcgtttct?gccactaagt?tgaatgatct?ttgcttctcc 1140
aatgtctatg?cagattcttt?tgtagtcaag?ggagatgatg?taagacaaat?agcgccagga 1200
caaactggtg?ttattgctga?ttataattat?aaattgccag?atgatttcat?gggttgtgtc 1260
c
ttgcttgga?atactaggaa?cattgatgct?acttcaactg?gtaattataa?ttataaatat 1320
aggtatctta?gacatggc
aa?gcttaggccc?tttgagagag?acatatctaa?tgtgcctttc 1380
tcccctgatg?gcaaaccttg?caccccacct?gctcttaatt?gttat
tggcc?attaaatgat 1440
tatggttttt?a
caccactac?tggcattggc?taccaacctt?acagagttgt?agtactttct 1500
tttgaacttt?taaatgcacc?ggccacggtt?tgtggaccaa?aattatccac?tgaccttatt 1560
aagaaccagt?gtgtcaattt?taattttaat?ggactcactg?gtactggtgt?gttaactcct 1620
tcttcaaaga?gatttcaacc?atttcaacaa?tttggccgtg?atgtttctga?tttcactgat 1680
tccgttcgag?atcctaaaac?atctgaaata?ttagacattt?caccttgcgc?ttttgggggt 1740
gtaagtgtaa?ttacacctgg?aacaaatgct?tcatctgaag?ttgctgttct?atatcaagat 1800
gttaactgca?ctgatgtttc?tacagcaatt?catgcagatc?aactcacacc?agcttggcgc 1860
atatattcta?ctggaaacaa?tgtattccag?actcaagcag?gctgtcttat?aggagctgag 1920
cat
gtcgaca?cttcttatga?gtgcgacatt?cctattggag?ctggcatttg?tgctagttac 1980
catacagttt?ctttat
tacg?tagtactagc?caaaaatcta?ttgtggctta?tactatgtct 2040
ttaggtgctg?atagttcaat?tgcttactct?aataacacca?ttgctatacc?tactaacttt 2100
tcaattagca?ttactacaga?agtaatgcct?gtttctatgg?ctaaaacctc?cgtagattgt 2160
aatatgtaca?tctgcggaga?ttctactgaa?tgtgctaatt?tgcttctcca?atatggtagc 2220
ttttgcacac?aactaaatcg?tgcactctca?ggtattgctg?ctgaacagga?tcgcaaca
ca 2280
cgtgaagtgt?tcgctcaagt?caaacaaatg?tacaaaaccc?caactttgaa?atattttggt 2340
ggttttaatt?tttcacaaat?attacctgac?cctctaaagc?caactaagag?gtcttttatt 2400
gaggacttgc?tctttaataa?ggtgacactc?gctgatgctg?gcttc
atgaa?gcaatatggc 2460
gaatgcctag?gtgatattaa?tgctag
agat?ctcatttgtg?cgcagaagtt?caatggactt 2520
acagtgttgc?cacctctgct?cactgatgat?atgattgctg?cctacactgc?tgctctagtt 2580
agtggtactg?ccactgctgg?atggacattt?ggtgctggcg?ctgctcttca?aatacctttt 2640
gctatgcaaa?
tggcatatag?gttcaatggc?attggagtta?cccaaaatgt?tctctatgag 2700
aaccaaaaac?aaatcgccaa?ccaatttaac?aaggcgatta?gtcaaattca?agaatcactt 2760
acaacaacat?caactgcatt?gggcaagctg?caagacgttg?ttaaccagaa?tgctcaagca 2820
ttaaacacac?ttgttaaaca?acttagctct?aattttggtg?caatttcaag?tgtgctaaat 2880
gatatcctt
t?cgcgacttga?t
aaagtcgag?gcggaggtac?aaattgacag?gttaattaca 2940
ggcagacttc?aaagccttca?aacctatgta?acacaacaac?taatcagggc?tgctgaaatc 3000
agggcttctg?ctaatcttgc?tgctactaaa?atgtctgagt?gtgttcttgg?acaatcaaaa 3060
agagttgact?tttgtggaaa?gggctaccac?cttatgtcct?tcccacaagc?agccccgcat 3120
ggtgttgtct?tcctacatgt?cacgtatgtg?ccatcccagg?agaggaactt?caccacagcg 3180
ccagcaattt?gtcatgaagg?caaagcatac?ttccctcgtg?aaggtgtttt?tgtgtttaat 3240
ggcacttctt?ggtttattac?acagaggaac?ttcttttctc?cacaaataat?tactacagac 3300
aatacatttg?tctcaggaaa?ttgtgatgtc?gttattggca?tcattaacaa?cacagtttat 3360
gatcctctgc?aacctgagct?tgactcattc?aaagaagagc?tggacaagta?cttcaaaaat 3420
catacatcac?cagatgttga?tcttggcgac?atttcaggca?ttaacgcttc?tgtcgtcaac 3480
attcaaaaag?aaattgaccg?cctcaatgag?gtcgctaaaa?atttaaatga?atcactcatt 3540
gaccttcaag?aattgggaaa?atatgagcaa?tatattaaat?ggccttggta?tgtttggctc 3600
ggcttcattg?ctggactaat?tgccatcgtc?atggttacaa?tcttgctttg?ttgcatgact 3660
agttgttgca?gttgcctcaa?gggt
gcatgc?tcttgtggtt?cttgctgcaa?gtttgatgag 3720
gatgactctg?agccagttct?caagggtgtc?aaattacatt?
acacataaac?gaacttatgg 3780
<210>2
<211>50
<212>DNA
＜213〉artificial sequence
<220>
＜223〉primer (a pair of) that is used for pcr amplification spike gene N end that designs according to spike gene base sequence
<400>2
ggtctagagt?tgtggtttca?agtgat
taggtaccaa?tgccagtagt?ggtg
<210>3
<211>50
<212>DNA
＜213〉artificial sequence
<220>
＜223〉primer (a pair of) that is used for pcr amplification spike gene M end that designs according to spike gene base sequence
<400>3
tttctagacc?atgggttgtg?tccttgct
ttggtacctc?cgcctcgact?tt
<210>4
<211>50
<212>DNA
＜213〉artificial sequence
<220>
＜223〉according to the primer that is used for pcr amplification spike gene M end of spike gene base sequence design (to)
<400>4
tttctagacc?atggcatata?ggttcaatg
ccggtaccat?aagttcgttt?atgtgt
Claims (18)
1, a kind of SARS vaccine is characterized in that it comprises SARS associated coronavirus S gene and replication-defective adenoviral.
2, SARS vaccine according to claim 1 is characterized in that defective adenoviral is 5 type adenoviruss of the C subclass that lacks fully of E1 district.
3, SARS vaccine according to claim 2 is characterized in that defective adenoviral is 5 type adenoviruss of the C subclass that lacks fully of E3 district.
4, SARS vaccine according to claim 2 is characterized in that defective adenoviral is 5 type adenoviruss of the C subclass of E3 district excalation.
5, SARS vaccine according to claim 2 is characterized in that defective adenoviral is 5 type adenoviruss of the C subclass that do not lack of E3 district.
6, SARS vaccine according to claim 1 and 2 is characterized in that dress CMV promoter and BGHpolyA in the defective adenoviral.
7, SARS vaccine according to claim 1 and 2 is characterized in that it comprises SARS associated coronavirus S full length gene.
8, SARS vaccine according to claim 1 and 2 is characterized in that being cloned into and comprises the sequence of S1 domain for SARS associated coronavirus S gene in the adenovirus vector.
9, SARS vaccine according to claim 1 and 2 is characterized in that being cloned into and comprises the sequence of S2 domain for SARS associated coronavirus S gene in the adenovirus vector.
10, SARS vaccine according to claim 1 and 2 is characterized in that being cloned into and comprises the sequence of S1, S2 domain for SARS associated coronavirus S gene in the adenovirus vector.
11, SARS vaccine according to claim 1 and 2, it is characterized in that being cloned in the adenovirus vector for base number be that 3686～3648 SARS associated coronavirus S gene is striden film district and C end fragment.
12, a kind of preparation method of SARS vaccine comprises
(1) obtains the S gene of SARS associated coronavirus;
(2) the S gene is combined with the defective adenoviral reorganization;
(3) transfection incasing cells;
(4) through amplification, separation, purification, make preparation.
13, SARS vaccine production method according to claim 12, it is characterized in that extracting the S gene after, it is cloned into the pshuttle plasmid, again it is connected combination with the adenovirus skeleton plasmid.
14, the preparation method of SARS vaccine according to claim 12 is characterized in that according to S gene order design PCR primer as follows:
v1 GGTCTAGAGT?TGTGGTTTCA?AGTGAT
v2 TTTCTAGACC?ATGGGTTGTG?TCCTTGCT
V3 TTTCTAGACC?ATGGCATATA?GGTTCAATG
V4 TAGGTACCAA?TGCCAGTAGT?GGTG
V5 TTGGTACCTC?CGCCTCGACT?TT
V6 CCGGTACCAT?AAGTTCGTTT?ATGTGT
15, SARS vaccine production method according to claim 12 is characterized in that incasing cells is cell line or a cell strain of having integrated C subclass 5 type adenovirus Ad5 E1 district genes.
16, SARS vaccine production method according to claim 15 is characterized in that incasing cells is 293 cells.
17, SARS vaccine production method according to claim 12 is characterized in that described preparation is spray or injection.
18, the application of SARS associated coronavirus S gene in the vaccine of preparation prevention SARS.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410044285 CN1276777C (en) | 2003-05-21 | 2004-05-18 | SARS vaccine of adenovirus carrier and preparation method, application of coronavirus S gene |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN03126634.7 | 2003-05-21 | ||
| CN03126634 | 2003-05-21 | ||
| CN 200410044285 CN1276777C (en) | 2003-05-21 | 2004-05-18 | SARS vaccine of adenovirus carrier and preparation method, application of coronavirus S gene |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1562365A CN1562365A (en) | 2005-01-12 |
| CN1276777C true CN1276777C (en) | 2006-09-27 |
Family
ID=34523618
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200410044285 Expired - Fee Related CN1276777C (en) | 2003-05-21 | 2004-05-18 | SARS vaccine of adenovirus carrier and preparation method, application of coronavirus S gene |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1276777C (en) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100479858C (en) * | 2005-01-27 | 2009-04-22 | 中国医学科学院实验动物研究所 | A recombined smallpox vaccine - SARS vaccine and preparation method thereof |
| WO2006079290A1 (en) * | 2005-01-27 | 2006-08-03 | Institute Of Laboratory Animal Science Of Chinese Academy Of Medical Sciences | A recombinant sars-cov vaccine comprising attenuated vaccinia virus carriers |
| CN101020055B (en) * | 2006-02-16 | 2012-08-08 | 中国疾病预防控制中心性病艾滋病预防控制中心 | SARS vaccine based on replicative vaccinia virus vector |
| CN102844663B (en) * | 2010-01-27 | 2016-01-06 | 俄勒冈健康科学大学 | Based on the immunogenic formulation of cytomegalovirus |
| CN111317816A (en) * | 2020-02-05 | 2020-06-23 | 翁炳焕 | Preparation method of novel coronavirus pneumonia bivalent vaccine |
| CN113248577B (en) * | 2020-02-12 | 2022-10-21 | 北京科兴中维生物技术有限公司 | Coronavirus vaccine using adenovirus as carrier and its preparing method |
| CN111228475A (en) * | 2020-02-21 | 2020-06-05 | 赛诺（深圳）生物医药研究有限公司 | Biological product for preventing novel coronavirus |
| US20220347289A1 (en) * | 2020-02-23 | 2022-11-03 | Guangzhou N Biomed Ltd. | Nucleotide sequences encoding peptide antigens of sars-cov-2 virus and use thereof |
| EP3922263A4 (en) * | 2020-03-16 | 2022-06-29 | Guangzhou N Biomed Ltd. | Ad7 vector vaccine for preventing sars-cov-2 infection |
| EP3912638A4 (en) * | 2020-03-16 | 2022-07-13 | Guangzhou N Biomed Ltd. | Ad35 vector vaccine for preventing sars-cov-2 infection |
| CN112206318B (en) * | 2020-03-16 | 2021-08-03 | 广州恩宝生物医药科技有限公司 | Ad7 vector vaccine for preventing SARS-CoV-2 infection |
| WO2021207962A1 (en) * | 2020-04-15 | 2021-10-21 | Active Motif Shanghai Limited | Antibodies to sars-coronavirus (covid-19) s1 spike protein |
| CN113750227A (en) * | 2020-06-01 | 2021-12-07 | 康希诺生物股份公司 | SARS-CoV-2 vaccine |
| CN112641937A (en) * | 2020-10-15 | 2021-04-13 | 广州达博生物制品有限公司 | Application of recombinant adenovirus in preparing medicine for preventing virus |
| CN112618707A (en) * | 2020-10-15 | 2021-04-09 | 广州达博生物制品有限公司 | SARS-CoV-2 coronavirus vaccine and its preparation method |
| CN114164220B (en) * | 2022-01-13 | 2022-08-12 | 广州达博生物制品有限公司 | Nucleotide sequence for constructing novel coronavirus vaccine and application thereof |
| CN114807179B (en) * | 2022-06-01 | 2022-10-21 | 广州达博生物制品有限公司 | Construction and application of novel coronavirus pneumonia vaccine |
-
2004
- 2004-05-18 CN CN 200410044285 patent/CN1276777C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN1562365A (en) | 2005-01-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1276777C (en) | SARS vaccine of adenovirus carrier and preparation method, application of coronavirus S gene | |
| Feng et al. | Canine parvovirus VP2 protein expressed in silkworm pupae self-assembles into virus-like particles with high immunogenicity | |
| CN1925870A (en) | DNA vaccine expressing HA1 of equine-2 influenza virus | |
| CN1275084A (en) | Recombinant porcine adenovirus vector | |
| CN1903363A (en) | Mosaic type virus-like particle DNA vaccine | |
| Tan et al. | Infectious bronchitis virus poly-epitope-based vaccine protects chickens from acute infection | |
| Jia et al. | Protective immunity of largemouth bass immunized with immersed DNA vaccine against largemouth bass ulcerative syndrome virus | |
| CN1730101A (en) | O type foot-and-mouth disease virus poly-gene duplication defect type adenovirus active carrier vaccine and preparation method | |
| CN1718242A (en) | The canine adenovirus type 2 recombiant vaccine of rabies virus sugar/structural protein such as nuclear | |
| CN1858062A (en) | Enzyme-linked immunosorbent test detecting reagent kit for non-structure protein of pig and cow foot and mouth disease virus | |
| Abid et al. | Generation and immunogenicity of a recombinant pseudorabies virus co-expressing classical swine fever virus E2 protein and porcine circovirus type 2 capsid protein based on fosmid library platform | |
| CN1933852A (en) | Improved inactivated FCV vaccines | |
| CN1763085A (en) | Avian infectious brunchitis virus s1 recombinant protein antigen, preparation method and uses | |
| CN114164220B (en) | Nucleotide sequence for constructing novel coronavirus vaccine and application thereof | |
| CN1276778C (en) | SARS nucleic acid vaccine and preparation method, application of S gene in coronavirus | |
| CN100335636C (en) | Thioredoxin gene of Schistosoma japonicum (Chinese Mainland Strain) and its cloning expression method and application | |
| CN1943789A (en) | The DNA vaccine of an anti-infection of hepatitis C virus | |
| CN1778812A (en) | Nolvac viral coat protein with recombinant rod virus expression and its preparation | |
| CN1761745A (en) | A novel human virus causing severe acute respiratory syndrome (SARS) and uses thereof | |
| CN1273482C (en) | Hepatitis C virus tunic protein E2 gene capable of being total length expressed in E. coli, its coding protein and use | |
| CN1239512A (en) | Replication-competent recombinant sabin type 1 strain of pollovirus | |
| CN1522760A (en) | Bivalent gene engineering vaccine of fowl infectious bursal disease and pasteurellosis | |
| CN1663616A (en) | Rotavirus gene vaccine based on NSP4 gene | |
| WO2013030608A1 (en) | Nanoparticle-based veterinary vaccine | |
| CN1778926A (en) | Modified pig propagation and respiratory syndrome virus ORF5 gene and use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Assignee: Shenzhen City Sibiono Gene Technology Co., Ltd. Assignor: Tumor Prevention and Therapy Center, Zhongshan Univ Contract fulfillment period: 2007.4.25 to 2024.5.17 contract change Contract record no.: 2008440000382 Denomination of invention: SARS vaccine of adenovirus carrier and preparation method, application of coronavirus S gene Granted publication date: 20060927 License type: Exclusive license Record date: 20081117 |
|
| LIC | Patent licence contract for exploitation submitted for record |
Free format text: EXCLUSIVE LICENSE; TIME LIMIT OF IMPLEMENTING CONTACT: 2007.4.25 TO 2024.5.17; CHANGE OF CONTRACT Name of requester: SHENZHEN CITY SAIBAINUO GENE TECHNOLOGY CO., LTD. Effective date: 20081117 |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20060927 Termination date: 20170518 |